MedTrace Logo

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

NCT00237393 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2008-02-21

No results posted yet for this study

Summary

The purpose of the study is to determine if quetiapine is effective in the treatment of PTSD.

Conditions

Interventions

DRUG

Quetiapine

Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.

DRUG

Placebo

Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Ralph H. Johnson VA Medical Center

    lead FED

Principal Investigators

  • Mark B Hamner, MD · Ralph H. Johnson VAMC/Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00237393 on ClinicalTrials.gov